Compare Recursion Pharmaceuticals Inc (RXRX) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Unilever plc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while Unilever plc trades at $62.45 (market cap $136.96B). The key difference: Unilever plc is far larger — about 73.6× Recursion Pharmaceuticals Inc's market cap, and Unilever plc pays a 3.34% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | UL | |
|---|---|---|
Market Cap | $1.86B | $136.96B |
Sector | Health | Consumer Staples |
52-Week High | $6.79 | $74.59 |
52-Week Low | $2.84 | $55.05 |
Enterprise Value | $1.38B | $162.94B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Unilever (UL) trades at $63.54, down 1.03% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $50.50 billion in 2025, with a net income margin of 18.32% and strong profitability metrics like ROE of 54.57%. Recent news highlights strategic partnerships in AI and a narrowed lawsuit with Ben & Jerry's, while Q2 2026 earnings showed 5.8% underlying sales growth, the strongest in a decade (Reuters, 2026-07-28).
Outlook is mixed: robust emerging market exposure and cost discipline support growth, but earnings misses and a net cash outflow of -$2.08 billion in 2025 pose risks. Analyst consensus is neutral with 51.36% hold ratings, reflecting cautious optimism amid execution challenges from portfolio simplification and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
